Lumicell illuminates cancer and other diseased tissues at the molecular level, enabling physicians to take action in real-time during surgeries to improve patient outcomes.
The company’s lead product, the Lumicell System, is in late-stage development for breast cancer surgery. It features an investigational optical agent and a handheld device that enable cancer surgeons to see and remove cancer cells in real-time during operations. The Lumicell System was designed and developed by MIT engineers in partnership with leading breast cancer surgeons to fit seamlessly within the existing surgical workflow. The Lumicell System is also under investigation for colorectal cancer, Barrett’s esophagus and brain metastases.